Ashesh Das

Dr. Ashesh Das

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
KMKareem A. Mohamed
Kareem A. Mohamed
Mohamed N. ElshabrawiMohamed N. Elshabrawi
Mohamed N. Elshabrawi
HMHossam Albeyoumi Mohammed
Hossam Albeyoumi Mohammed
MKMohamed Khalil
Mohamed Khalil
AAAhmed AlGhazawy
Ahmed AlGhazawy
Akshay KumarAkshay Kumar
Akshay Kumar
Background: Resistant hypertension represents a significant clinical challenge, often driven by dysregulated aldosterone production. Aldosterone synthase inhibitors (ASIs) are a novel therapeutic class designed to directly suppress aldosterone biosynthesis. This study aimed to synthesize evidence regarding the comparative efficacy, optimal dosing, and dose–response relationships of three ASIs—baxdrostat, lorundrostat, and osilodrostat—for the treatment of resistant hypertension. Methods: A systematic review and network meta-analysis (NMA) were conducted following PRISMA 2020 guidelines. We searched PubMed, Web of Science, and CENTRAL for randomized controlled trials (RCTs) published up to 31 October 2025. The primary outcome was the mean change in systolic blood pressure (SBP) compared to placebo. We utilized a frequentist random-effects model, characterized dose–response relationships via meta-regression, and ranked treatments using the Surface Under the Cumulative Ranking Curve (SUCRA). Results: The analysis included 8 RCTs comprising 3253 participants. Baxdrostat 2 mg once daily demonstrated the greatest antihypertensive efficacy with a mean SBP reduction of −13.8 mmHg (95% CI: −17.5 to −10.1) versus placebo, followed by Lorundrostat 100 mg (−12.5 mmHg) and Baxdrostat 1 mg (−11.5 mmHg). SUCRA analysis identified Baxdrostat as the highest-ranked treatment (83.0%), followed by Lorundrostat (67.8%) and Osilodrostat (55.5%). Dose–response meta-regression revealed strong linear correlations for Baxdrostat (R2 = 0.91), Osilodrostat (R2 = 0.81), and Lorundrostat (R2 = 0.80). Conclusions: ASIs, particularly Baxdrostat and Lorundrostat, offer robust blood pressure reductions in patients with resistant hypertension. The strong linear dose–response relationships suggest these agents have a favorable therapeutic window for titration. While effective, clinical implementation requires careful monitoring for adverse events.

2 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
SKSharanya Kumar
Sharanya Kumar
ARAkash Rawat
Akash Rawat
KSKeerthi Sanapala
Keerthi Sanapala
KAK A Alisha
K A Alisha
SDSonam Dhall
Sonam Dhall
RKRakhshanda Khan
Rakhshanda Khan
Introduction: Cushing’s disease (CD) is a rare endocrine disorder characterized by excessive cortisol production due to a pituitary adenoma secreting ACTH, leading to a range of systemic effects including obesity, hypertension, and hyperglycemia. The condition is often underdiagnosed, with an incidence of 2-3 cases per million people annually. While surgery remains the first-line treatment, adjunctive medical therapies are essential for non-surgical candidates or those with recurrent disease. This systematic review and network meta-analysis (NMA) evaluate the comparative efficacy and safety of medical treatments for Cushing’s disease. Methods: A comprehensive literature search was conducted across PubMed, Scopus, Cochrane Library, and Web of Science for randomized controlled trials (RCTs) and observational studies published between 2010 and 2023. Studies were included if they assessed the efficacy and/or safety of medical treatments for Cushing’s disease. Data extraction was performed independently by two reviewers. Risk of bias was assessed using the Cochrane Risk of Bias tool for RCTs and ROBS 2.0 for observational studies. Network meta-analysis was performed using a random-effects model to compare treatments across different outcomes. Results: A total of 29 studies involving 1,736 patients were included in the analysis. The patient cohort comprised 600 males (34.5%) and 1,132 females (65.5%), with an average age of 41.09 years. Among the treatments, 960 patients (55.3%) received Pasireotide, 143 (8.2%) Osilodrostat, 126 (7.3%) Mifepristone, and 176 (10.1%) Levoketoconazole. In terms of 24-hour urinary free cortisol (UFC) reduction, Levoketoconazole showed a mean difference of -329 (95% CI: -2.33e+03, 1.70e+03), Mifepristone -381 (95% CI: -3.27e+03, 1.74e+03), Osilodrostat -214 (95% CI: -1.60e+03, 1.25e+03), and Pasireotide -331 (95% CI: -1.75e+03, 1.09e+03). Despite all treatments reducing UFC levels, the broad confidence intervals suggest substantial uncertainty in the efficacy estimates. Regarding the change in cortisol levels, Mifepristone showed a mean difference of 290 (95% CI: -285, 888), Osilodrostat 15.6 (95% CI: -806, 835), and Pasireotide -6.17 (95% CI: -821, 815), indicating considerable variability in treatment effects. The analysis of ACTH levels revealed similar trends, with Levoketoconazole and Mifepristone showing more pronounced reductions compared to Osilodrostat. In terms of overall survival, Levoketoconazole demonstrated a survival rate of 0.82 (95% CI: 0.72–0.91), while Mifepristone had a pooled survival rate of 0.94 (95% CI: 0.86–1.02). The analysis of disease-free survival indicated an overall pooled survival rate of 0.80 (95% CI: 0.70–0.90). Quality of life (QOL) improvements were variable, with Osilodrostat showing a mean difference of -11.72 (95% CI: -18.32, -5.12). There were no significant differences in the risk of gastrointestinal, cardiovascular, or neurological adverse events between treatments. Conclusion: This systematic review and network meta-analysis provide valuable insights into the comparative efficacy and safety of medical treatments for Cushing’s disease. While Pasireotide and Levoketoconazole consistently reduce UFC levels, Mifepristone and Osilodrostat also show potential, albeit with greater variability in clinical outcomes. The high heterogeneity observed across studies suggests the need for further research to refine treatment strategies and optimize patient management. Personalized treatment approaches, incorporating both efficacy and safety considerations, will be crucial for improving outcomes and minimizing the burden of this disease.

14 October 2026 in European Journal of Medical Research
Verified
Journal Article
Open access
PDF file
ADAshesh Das
Ashesh Das
JNJared M. Nicholoff
Jared M. Nicholoff
NHNoorul Hidhaya
Noorul Hidhaya
JSJasmeet Singh
Jasmeet Singh
DFDadullah Faiz
Dadullah Faiz
SMShreya Muddana
Shreya Muddana
Recurrent overt hepatic encephalopathy (HE) in cirrhosis remains a major clinical challenge despite standard therapies including lactulose and rifaximin. E

31 August 2026 in Journal of Robotic Surgery
Verified
Journal Article
Closed access
PDF file
ADAshesh Das
Ashesh Das
MYMeenakshi Reddy Yathindra
Meenakshi Reddy Yathindra
MMMujtaba Moazzam
Mujtaba Moazzam
SPSwaraj Paul
Swaraj Paul
NSNoorin Riya Tharupeedikayil Sageer
Noorin Riya Tharupeedikayil Sageer
FKFaiza Khalid
Faiza Khalid

25 July 2026 in Journal of Thrombosis and Thrombolysis
Verified
Journal Article
Closed access
PDF file
MKMuneeb Khawar
Muneeb Khawar
MEMohab Elnashar
Mohab Elnashar
MKMirza Muhammad Hadeed Khawar
Mirza Muhammad Hadeed Khawar
MMMohammad Azeem Malik
Mohammad Azeem Malik
SGShameer Iqbal Ghuman
Shameer Iqbal Ghuman
ADAshesh Das
Ashesh Das

18 September 2025 in medRxiv
Verified
Preprint
Open access
PDF file
HRHarshawardhan Dhanraj Ramteke
Harshawardhan Dhanraj Ramteke
SKSanapala Keerthi
Sanapala Keerthi
ADAshesh Das
Ashesh Das
BSBodanam Shreya
Bodanam Shreya
SPShameek Paul
Shameek Paul
RKRakhshanda Khan
Rakhshanda Khan
Introduction: Achalasia is a rare primary esophageal motility disorder characterized by impaired lower esophageal sphincter relaxation and dysphagia. Laparoscopic Heller myotomy (LHM) has long been the standard treatment, while peroral endoscopic myotomy (POEM) has emerged as a minimally invasive alternative. Comparative evidence from randomized controlled trials (RCTs) remains limited, and outcomes such as gastroesophageal reflux disease (GERD) and clinical remission require clarification. Methods: We systematically searched PubMed, Embase, Cochrane CENTRAL, and Web of Science to September 2025 for RCTs comparing POEM and LHM in adult patients with achalasia. Data on demographics, previous treatment, dysphagia improvement, GERD incidence, clinical remission, and mortality were extracted. Pooled odds ratios (OR) with 95% confidence intervals (CI) were calculated using a random-effects model in Stata 18. Results: Seven RCTs involving 900 patients (465 POEM; 465 LHM) were included. Dysphagia improvement was similar between groups (log OR 0.14; 95% CI −0.32 to 0.59; p = 0.55). GERD incidence was higher after POEM but not statistically significant (log OR 0.59; 95% CI −0.08 to 1.25; p = 0.08). Clinical remission showed a non-significant trend favoring POEM (log OR 0.39; 95% CI −0.06 to 0.84; p = 0.09). Reduction in pH levels significantly favored LHM (log OR 0.75; 95% CI 0.18 to 1.33; p = 0.01). No mortality was reported. Conclusion: POEM and LHM provide comparable dysphagia relief and clinical remission in achalasia. However, POEM is associated with higher GERD risk, particularly on pH monitoring. Treatment choice should balance efficacy against reflux risk, with careful long-term follow-up.